# Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

> **NCT02716103** · — · COMPLETED · sponsor: **Boston Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **OTHER:** blood collection
- **OTHER:** bone marrow collection

## Key facts

- **NCT ID:** NCT02716103
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-21
- **Primary completion:** 2020-09-04
- **Final completion:** 2020-09-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716103, "Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02716103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*